Anhui Anke Biotechnology (Group) Co., Ltd. Class A

Anhui Anke Biotechnology (Group) Co., Ltd. Class A

SSZSE:300009
7.63
CNY
-0.07
(-0.91%)
0.40EPS
22.09P/E
14.38BMarket Cap
Apr 01Next Earn

Total Valuation

CNY

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A carries a market capitalization of 14.38B, placing it among publicly traded companies globally. Its enterprise value stands at 13.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.38B
Enterprise Value13.20B

Important Dates

Anhui Anke Biotechnology (Group) Co., Ltd. Class A's next confirmed earnings release is scheduled for April 1, 2027.

Earnings Date4/1/2027

Share Statistics

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A has 1.67B shares outstanding.

Shares Outstanding1.67B

Valuation Ratios

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 22.09. The price-to-sales ratio is 6.16, and the price-to-book ratio stands at 3.28.

PE Ratio22.09
PS Ratio6.16
PB Ratio3.28
P/TBV Ratio3.87

Enterprise Valuation

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A trades at an EV/EBITDA multiple of 17.83 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.83 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 13.20B versus a market cap of 14.38B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.65
EV / EBITDA17.83
EV / EBIT17.83

Financial Position

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A maintains a current ratio of 4.21, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.70, indicating elevated leverage, while an interest coverage ratio of 416.82 demonstrates strong ability to service its debt obligations.

Current Ratio4.21
Quick Ratio2.38
Debt / Equity1.70
Debt / EBITDA0.10
Interest Coverage416.82

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A posted a return on equity (ROE) of 15.61, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.94, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.74, useful for judging operating efficiency across full business cycles. The company generates approximately 932,602.47 in revenue per employee across its workforce of 2,505.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.94 indicates how many times Anhui Anke Biotechnology (Group) Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)15.61
Return on Assets (ROA)12.94
Return on Invested Capital (ROIC)15.12
Return on Capital Employed (ROCE)14.74
Revenue Per Employee932,602.47
Employee Count2,505.00
Inventory Turnover1.94

Taxes

CNY

Over the twelve months ended September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A recorded 72.01M in income tax expense. That works out to an effective tax rate of 9.79, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 735.37M, leaving 651.66M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax72.01M
Effective Tax Rate9.79

Stock Price Statistics

CNY

As of the close on November 17, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A's stock has declined approximately 27.81% over the past 52 weeks. The 50-day moving average sits at 8.11, while the 200-day moving average is 8.74.

52-Week Price Change-27.81%
50-Day Moving Average8.11
200-Day Moving Average8.74

Income Statement

CNY

Over the twelve months ended September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A generated 2.34B in revenue and converted that into 651.66M in net income, yielding earnings per share of 0.40. EBITDA reached 740.01M, while operating income came in at 741.55M.

Revenue2.34B
Gross Profit1.76B
Operating Income741.55M
Pretax Income735.37M
Net Income651.66M
EBITDA740.01M
EBIT740.01M
Earnings Per Share (EPS)0.40

Balance Sheet

CNY

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A holds 1.32B in cash and equivalents against 75.61M in total debt, resulting in a net debt position of -129.88M. Total book value stands at 4.38B, with working capital of 1.79B providing operational flexibility.

Cash & Cash Equivalents1.32B
Total Debt75.61M
Net Debt-129.88M
Equity (Book Value)4.38B
Book Value Per Share2.62
Working Capital1.79B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-152.49M

Margins

Over the twelve months ended September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A posted a gross margin of 75.29, reflecting its pricing power and cost economics. The operating margin of 31.74 and net profit margin of 27.89 provide insight into operational efficiency.

Gross Margin75.29
Operating Margin31.74
Pretax Margin31.48
Profit Margin27.89
EBITDA Margin31.68

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A paid dividends of 0.26 per share. The dividend payout ratio of 63.33 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Anhui Anke Biotechnology (Group) Co., Ltd. Class A shareholders.

Dividend Per Share0.26
Payout Ratio63.33
Shareholder Yield3.85

Stock Splits

Anhui Anke Biotechnology (Group) Co., Ltd. Class A's most recent stock split took place on May 14, 2021 with a 5:6 split ratio.

Last Split Date5/14/2021
Split Ratio5:6

Scores

As of September 30, 2026, Anhui Anke Biotechnology (Group) Co., Ltd. Class A has an Altman Z-Score of 14.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score14.32